Trial Profile
Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Anidulafungin (Primary) ; Fluconazole; Voriconazole
- Indications Candidaemia; Invasive candidiasis
- Focus Therapeutic Use
- Sponsors Pfizer
- 23 Apr 2021 Results Results of post hoc pooled analysis from NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; evaluating patient level efficacy and safety data of anidulafungin, published in the Clinical Drug Investigation
- 19 Mar 2020 Results (N=163) pharmacokinetic of Anidulafungin in pooled population analysis from 4 studies, published in the Clinical Pharmacology and Therapeutics
- 06 Jul 2019 Results of post hoc pooled analysis determining the efficacy and safety of anidulafungin treatment in patients with intra abdominal candidiasis from five prospective studies (NCT00496197, NCT00548262, NCT00537329,NCT00689338 and NCT00805740) published in the European Journal of Clinical Microbiology and Infectious Diseases